Stem cell's shell game?
By Capitol Weekly,
Capitol Weekly
| 09. 22. 2005
The biggest question surrounding stem cell research in California right now isn_t whether it will eventually cure devastating health problems. It_s what happened to the billion dollars.
When California voters approved Proposition 71 last year, critics say, it was partially on the promise that their $3 billion investment in stem cell research would provide a financial payoff to the state. Supporters cited a study that claimed California could get a payback of anywhere between $537 million and $1.1 billion from royalties and licensing from intellectual property, or IP, as it is known in the investment community.
Actually, the figures were never written into the law that voters approved--the latest surprise disclosure surrounding the controversial initiative. And the study itself was financed by the backers of Proposition 71.
That means perhaps $1 billion or more that many expected Proposition 71 to provide to California may not be coming, after all. The numbers came from a September 2004 analysis produced by Dr. Laurence Baker, an associate professor of the Stanford University School of Medicine, and Bruce Deal, managing partner of the Analysis...
Related Articles
By Emma McDonald Kennedy
| 10.29.2026
At the beginning of Nathan Fielder and Lance Oppenheim’s blockbuster documentary You Can See Everything, Billy Evans (partner of Theranos founder and convicted fraudster Elizabeth Holmes), says that they decided to do the film for one purpose: “radical transparency.” As they work on “Theranos 2.0,” Evans and Holmes want to show the public that she has been misunderstood –– painted as a liar and a fraud in the public imagination (and the courts) despite, as she claims in the...
By Charles Schmidt, Undark | 09.25.2026
In 2010, scientists at the University of Tokyo and other institutions reported a startling achievement: They had successfully grown a pancreas made almost entirely of rat cells within the bodies of mice. The research was directed by Hiromitsu Nakauchi, a...
By Editors, Nature | 08.18.2026
Shinya Yamanaka doesn’t see himself as a celebrity. But people do recognize the stem-cell researcher when he’s out for a run, often while training for a marathon, on the streets of Kyoto, Japan.
Many of them call out words of...
By Jessica Hamzelou, MIT Technology Review | 07.30.2026
As of this week in Montana, any biotech company with an experimental drug has a clear path to selling it to consumers. Companies whose drugs have been through preliminary testing—sometimes in as few as 10 healthy people—can pay $12,500 to...